Custom Search

Sunday, April 22, 2012

Type 2 Diabetes : ChREBP-β gene could be new target for new drugs for treatment of Type 2 Diabetes

Type 2 diabetes development linked to higher expression of gene responsible for insulin resistance in fatty tissuse. 

Diabetes is a disease which is developed over the period of time, as glucose present in blood is not mobilized in to body tissue viz, fat cells and muscles. Increase blood glucose level disrupts normal health and lead towards development of subsequent diseases like hyper tension, aging and muscular weakness and so on.

Insulin is a hormone in our body which regulates mobilization of blood glucose in to muscle and fat cells, it act upon muscle and fatty tissue cells , adipose tissue cells and trigger activation of protein molecules called as Glucose transporter type4 GLUT4 which facilitate transportation of glucose in to fat and muscle cells in our body, where glucose is used a source of energy and for tissue building. 

There are following types of diabetes 
 Type 1 Diabetes: Pancreas is not able to produce sufficient amount of Insulin, it may be because of several genetic factors and autoimmune diseases where cells producing insulin in pancreases are destroyed.

Type 2 Diabetes: In this type of diabetes peripheral muscle cells and fat cells produce resistance towards action of insulin or effect of insulin with respect to transportation of glucose is reduced, which is also related to Glucose transporter type 4 GLUT4.

Drs. Barbara Kahn and Mark Herman from Harvard Medical School and Beth Israel Deaconess Medical Center and their team have found that a gene ChREBP-β expressed highly which can be related to insulin resistance.

The high concentration of Glucose transporter type 4 GLUT4 which is responsible for mobilization and fatty tissue building . is related to higher expression of gene responsible ChREBP, and its other form gene ChREBP-β which was found in high level in mice feed with high fat diet, and in adipose tissue of individuals with insulin resistance therefore can be related to development of insulin resistance and obesity.

Higher expression of ChREBP-β is related to insulin resistance in fatty tissue therefore in future it could be one of target for developing a new drug to treat type 2 diabetes.

You may also like:


Insulin now provides hope for treatment of Alzheimer’s disease

Transdermal drug delivery system new requirements for quality and for regulatory submissions

New treatment discovered for making kidney transplant successful.

Liposomal drug delivery system

A new vaccine for TB which can provide protection in late stage infection.

Protein which is responsible for cancer spread discovered An antisense RNA treatment or a drug could be designed to treat cancer efficiently and safely.

Novel Drugs: Cancer Chemotherapy Using Nanoparticles May Reduce Harmful Side Effects.

What is Nanotechnology, its applications in medicine and pharmaceuticals, drug developments?

No comments:

Posted by: Martin

How to sucessfuly activate and receive our articles on pharmaceuticals by E-Mail

Dear readers if you wish to receive our articles on pharmaceutical automatically into your email Inbox , as and when we write a new article over this website, then follow these 3 simple steps.


1.You should write your Email ID in the box provided and push the subscribe butten


2.Enter the text code that we show you in a small new browser window after you enter your email ID.

3.Log in to your email and Cheke our verification email sent by "FEEDBURNER" , there you should verify the link we send you by email.




Enter your email address get our articles by email whenever this website is updated





Delivered by FeedBurner



Join the list of our readers from Universities ,Research and Development centers Pharmaceutical Companies from all over the world.











Pharma Research Regulatory Guidelines Website
Texas Dallas, TX 75211 US
Email: editor@pharmacistspharmajournal.org Website: http://pharmacistspharmajournal.org/
Copyright © 2008-2015 all rights reserve www.pharmacistspharmajournal.org